Smith TR et al. (2005) Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 45: 983–991
A prospective multicenter study—one of the first of its kind—has shown encouraging results for a combined acute treatment for migraine, involving a triptan and an analgesic.
Smith et al. treated a cohort of 972 patients, containing both males and females, in their four-arm, double-blind study. The patients were randomly assigned to treatment with placebo, naproxen sodium 500 mg, sumatriptan 50 mg, or a combination of the two drugs at the aforementioned doses. At the onset of a moderate or severe migraine attack, patients completed study diary cards before taking their assigned medication. They then completed diary cards at 15 min intervals for up to 2 hours, and at 30 min intervals 2–4 hours after medication.
The primary endpoint of the study was a 'sustained pain response'. This was achieved in 46% of patients assigned to the combination therapy—significantly greater than that achieved in the patients taking sumatriptan (29%), naproxen sodium (25%), or placebo (17%) (P <0.001). Headache response after 2 hours was also significantly higher in patients treated with combined medication than in those treated with sumatriptan, naproxen sodium, or placebo (65% vs 49%, 46% and 27%, respectively; P <0.001).
The authors suggest that multimechanism acute treatment for migraine using a triptan and an analgesic offers improved clinical benefits over monotherapy with these medications, and is well tolerated and not associated with a significant increase in adverse events compared with monotherapy.
Rights and permissions
About this article
Cite this article
Kyme, C. Multimechanism approach benefits treatment of migraine. Nat Rev Neurol 1, 66 (2005). https://doi.org/10.1038/ncpneuro0020
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0020